UPDATE : Thursday, May 23, 2019
상단여백
‘Risk-sharing agreements back up economic feasibility review’ by Kim Yun-mi 2019-05-22 14:46
Japan issued safety warning on Lilly’s breast cancer drug. Will Korea, too? by Kim Yun-mi 2019-05-21 14:19
Low-income, single women more vulnerable to osteoporosis by Kim Yun-mi 2019-05-20 15:40
Latecomer SGLT2 inhibitor Steglatro unlikely to get free ride by Kim Yun-mi 2019-05-15 15:30
Keytruda wins nod as adjuvant therapy after melanoma surgery by Kim Yun-mi 2019-05-15 14:14
라인
Antibody-drug conjugates on the rise as Herceptin’s patent to expire soon by Kim Yun-mi 2019-05-13 14:23
Xeljianz is easier to use than biologic therapies -- is it safer, however? by Kim Yun-mi 2019-05-10 15:34
[Exclusive] MSD Korea playing tricks to reduce daycare cost by Kim Yun-mi 2019-05-09 11:20
[Reporter’s Notebook] Roche agreed, MSD and BMS should, too by Kim Yun-mi 2019-05-07 14:30
Leading hepatitis C drug wins FDA nod for adolescents by Kim Yun-mi 2019-05-03 15:51
라인
New head of HUMC to put focus on research by Kim Yun-mi 2019-05-02 16:57
‘MSD Korea’s monitoring program might be privacy breach’ by Kim Yun-mi 2019-05-02 11:00
Drugmakers brace for vaccine shortage amid surging hepatitis A cases by Kim Yun-mi 2019-04-30 13:13
Breast cancer society to focus on patients’ quality of life by Kim Yun-mi 2019-04-26 14:22
‘PD-L1 expression poor marker for bladder cancer’s immunotherapy’ by Kim Yun-mi 2019-04-25 11:52
라인
[News Focus] Cholesterol-reducing PCSK9 inhibitors get popular -- cost-effective, too? by Kim Yun-mi 2019-04-24 12:35
How to improve treatment guidelines for dyslipidemia? by Kim Yun-mi 2019-04-22 14:50
‘No need to reduce number of drugs for triple-drug therapy to treat HIV’ by Kim Yun-mi 2019-04-18 15:20
Novartis’ new macular degeneration drug has to compete against colon cancer drug Avastin. Why? by Kim Yun-mi 2019-04-18 14:42
Immunotherapies’ liver cancer-treating effects confirmed in real-world studies by Kim Yun-mi 2019-04-15 14:29
여백
여백
여백
Back to Top